Leukotrienes in pulmonary arterial hypertension

Immunologic Research

Volumn 58, Issue 2-3, 2014, Pages 387-393

  Tian, Wen ^a   Jiang, Xinguo ^a   Sung, Yon K ^a   Qian, Jin ^a   Yuan, Ke ^b   Nicolls, Mark R ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Lipoxygenase; Inflammation; Leukotriene; Pulmonary arterial hypertension; Vascular remodeling

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; LEUKOTRIENE; LEUKOTRIENE B4; ARACHIDONATE 5 LIPOXYGENASE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2;

PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; ANIMAL; BIOSYNTHESIS; GENETICS; HUMAN; METABOLISM; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; HUMANS; HYPERTENSION, PULMONARY; LEUKOTRIENES; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

EID: 84901609808     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8492-5     Document Type: Review

References (80)

1. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164-72.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336(2):111-7. (Pubitemid 27020889)
3. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol. 1995;75(3):51A-4A.
4. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):40S-7S. (Pubitemid 38759716)
5. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8(8):443-55.
6. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(1 Suppl):S10-9.
7. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005;26(6):1110-8. (Pubitemid 41829945)
8. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med. 2007;175(12):1280-9. (Pubitemid 46905754)
9. Peters-Golden M, Henderson WR Jr. Leukotrienes. New Engl J Med. 2007;357(18):1841-54.
10. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol. 2005;174(2):589-94. (Pubitemid 40103563)
11. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2-3):99-109. (Pubitemid 36976166)
12. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene biosynthesis.AmJRespirCritCareMed. 2000;161(2Pt 2):S36-40. (Pubitemid 30129413)
13. Samuelsson B, Funk CD. Enzymes involved in the biosynthesis of leukotriene B4. J Biol Chem. 1989;264(33):19469-72.
14. Fitzpatrick FA, Liggett WF, Wynalda MA. Albumin-eicosanoid interactions. A model system to determine their attributes and inhibition. J Biol Chem. 1984;259(5):2722-7. (Pubitemid 14163131)
15. Yokomizo T, Uozumi N, Takahashi T, Kume K, Izumi T, Shimizu T. Leukotriene A4 hydrolase and leukotriene B4 metabolism. J Lipid Mediat Cell Signal. 1995;12(2-3):321-32.
16. Shimizu T, Izumi T, Seyama Y, Tadokoro K, Radmark O, Samuelsson B. Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. Proc Natl Acad Sci USA. 1986;83(12):4175-9. (Pubitemid 16057014)
17. Izumi T, Minami M, Ohishi N, Bito H, Shimizu T. Site-directed mutagenesis of leukotriene A4 hydrolase: distinction of leukotriene A4 hydrolase and aminopeptidase activities. J Lipid Mediat. 1993;6(1-3):53-8.
18. Minami M, Ohno S, Kawasaki H, Radmark O, Samuelsson B, Jornvall H, Shimizu T, Seyama Y, Suzuki K. Molecular cloning of a cDNA coding for human leukotriene A4 hydrolase. Complete primary structure of an enzyme involved in eicosanoid synthesis. J Biol Chem. 1987;262(29):13873-6. (Pubitemid 17152083)
19. Shimizu T, Izumi T, Ohishi N, Seyama Y, Kitamura S. Biosynthesis and further transformations of leukotriene A4. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:64-8.
20. Hammerstrom S, Samuelsson B. Detection of leukotriene A4 as an intermediate in the biosynthesis of leukotrienes C4 and D4. FEBS Lett. 1980;122(1):83-6. (Pubitemid 11180983)
21. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548):1871-5. (Pubitemid 33101574)
22. Radmark O, Malmsten C, Samuelsson B. Leukotriene A4: enzymatic conversion to leukotriene C4. Biochem Biophys Res Commun. 1980;96(4):1679-87.
23. Orning L, Hammarstrom S. Inhibition of leukotriene C and leukotriene D biosynthesis. J Biol Chem. 1980;255(17):8023-6. (Pubitemid 11245922)
24. Malmsten CL, Palmblad J, Uden AM, Radmark O, Engstedt L, Samuelsson B. Leukotriene B4: a highly potent and stereospecific factor stimulating migration of polymorphonuclear leukocytes. Acta Physiol Scand. 1980;110(4):449-51. (Pubitemid 11135997)
25. Sha'afi RI, Naccache PH, Molski TF, Borgeat P, Goetzl EJ. Cellular regulatory role of leukotrieneB4: its effects on cation homeostasis in rabbit neutrophils. J Cell Physiol. 1981;108(3):401-8. (Pubitemid 11017801)
26. Henderson WR, Jorg A, Klebanoff SJ. Eosinophil peroxidase-mediated inactivation of leukotrienes B4, C4, and D4. J Immunol. 1982;128(6):2609-13.
27. Czarnetzki BM. Is eosinophil chemotactic factor identical with leukotriene B? Int Arch Allergy Appl Immunol. 1982;67(2):181-3. (Pubitemid 12169645)
28. Jorg A, Henderson WR, Murphy RC, Klebanoff SJ. Leukotriene generation by eosinophils. J Exp Med. 1982;155(2):390-402. (Pubitemid 12171286)
29. Murphy RC, Mathews WR. Purification and characterization of leukotrienes from mastocytoma cells. Methods Enzymol. 1982;86:409-16.
30. Holgate ST, Church MK. Control of mediator release from mast cells. Clin Allergy. 1982;12(Suppl):5-13. (Pubitemid 13254358)
31. Hsueh W, Sun FF. Leukotriene B4 biosynthesis by alveolar macrophages. Biochem Biophys Res Commun. 1982;106(4):1085-91.
32. Doig MV, Ford-Hutchinson AW. The production and characterisation of products of the lipoxygenase enzyme system released by rat peritoneal macrophages. Prostaglandins. 1980;20(6):1007-19. (Pubitemid 11189718)
33. Fels AO, Pawlowski NA, Cramer EB, King TK, Cohn ZA, Scott WA. Human alveolar macrophages produce leukotriene B4. Proc Natl Acad Sci USA. 1982;79(24):7866-70. (Pubitemid 13182480)
34. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol. 2002;64(11):1549-57. (Pubitemid 35339376)
35. Yokomizo T, Masuda K, Kato K, Toda A, Izumi T, Shimizu T. Leukotriene B4 receptor. Cloning and intracellular signaling. Am J Respir Crit Care Med. 2000;161(2 Pt 2):S51-5. (Pubitemid 30129416)
36. Izumi T, Yokomizo T, Igarashi T, Shimizu T. Molecular cloning and characterization of leukotriene B4 receptor. Adv Exp Med Biol. 1999;469:237-44.
37. Crooke ST, Mattern M, Sarau HM, Winkler JD, Balcarek J, Wong A, Bennett CF. The signal transduction system of the leukotriene D4 receptor. Trends Pharmacol Sci. 1989;10(3):103-7. (Pubitemid 19076878)
38. Cristol JP, Provencal B, Sirois P. Leukotriene receptors. J Recept Res. 1989;9(4-5):341-67. (Pubitemid 20066438)
39. Metters KM. Leukotriene receptors. J Lipid Mediat Cell Signal. 1995;12(2-3):413-27.
40. Lipworth BJ. Leukotriene-receptor antagonists. Lancet. 1999;353(9146):57-62. (Pubitemid 29037713)
41. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, Koller BH, Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest. 1996;97(11):2491-8.
42. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;157(1):219-29. (Pubitemid 28071286)
43. Jones JE, Walker JL, Song Y, Weiss N, Cardoso WV, Tuder RM, Loscalzo J, Zhang YY. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2004;286(5):H1775-84. (Pubitemid 38525466)
44. Runo JR, Vnencak-Jones CL, Prince M, Loyd JE, Wheeler L, Robbins IM, Lane KB, Newman JH, Johnson J, Nichols WC, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med. 2003;167(6):889-94. (Pubitemid 36801778)
45. Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N, Manes A, Corris P, Simonneau G, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006;27(2):212-3.
46. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004;43(12 Suppl S):33S-9S. (Pubitemid 38759715)
47. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L450-8. (Pubitemid 43725089)
48. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation. 2005;112(4):553-62. (Pubitemid 41060796)
49. Radmark O, Samuelsson B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun. 2010;396(1):105-10.
50. Werz O, Klemm J, Samuelsson B, Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA. 2000;97(10):5261-6. (Pubitemid 30313706)
51. Radmark O, Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. J Lipid Res. 2009;50(Suppl):S40-5.
52. Werz O, Szellas D, Steinhilber D, Radmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem. 2002;277(17):14793-800. (Pubitemid 34959961)
53. Tabata T, Ono S, Song C, Noda M, Suzuki S, Tanita T, Fujimura S. Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35(2):160-6. (Pubitemid 27166542)
54. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med. 2013;5(200):200ra117.
55. Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci. 2005;118(Pt 20):4605-12. (Pubitemid 41646371)
56. Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res. 2009;77(1):39-45.
57. Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J. Sphingosine-1-phosphate: a bioactive lipid that confers highdensity lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost. 2009;101(4):665-73.
58. Gonzalez-Diez M, Rodriguez C, Badimon L, Martinez-Gonzalez J. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost. 2008;100(1):119-26. (Pubitemid 351948753)
59. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, Barbour SE, Milstien S, Spiegel S. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J. 2008;22(8):2629-38.
60. Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation. 2005;112(4):578-86. (Pubitemid 41060799)
61. Orning L, Krivi G, Fitzpatrick FA. Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J Biol Chem. 1991;266(3):1375-8. (Pubitemid 21908311)
62. Muskardin DT, Voelkel NF, Fitzpatrick FA. Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase. Biochem Pharmacol. 1994;48(1):131-7. (Pubitemid 24236401)
63. Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother. 1986;23(1):5-10. (Pubitemid 16018442)
64. Ota K, Uzuka Y. Clinical trials of bestatin for leukemia and solid tumors. Biotherapy. 1992;4(3):205-14.
65. Rao NL, Dunford PJ, Xue X, Jiang X, Lundeen KA, Coles F, Riley JP, Williams KN, Grice CA, Edwards JP, et al. Antiinflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther. 2007;321(3):1154-60. (Pubitemid 46762702)
66. Whittle BJ, Varga C, Berko A, Horvath K, Posa A, Riley JP, Lundeen KA, Fourie AM, Dunford PJ. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol. 2008;153(5):983-91. (Pubitemid 351328940)
67. Marder P, Spaethe SM, Froelich LL, Cerimele BJ, Petersen BH, Tanner T, Lucas RA. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist. Br J Clin Pharmacol. 1996;42(4):457-64. (Pubitemid 26340146)
68. Marder P, Sawyer JS, Froelich LL, Mann LL, Spaethe SM. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy] benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist. Biochem Pharmacol. 1995;49(11):1683-90.
69. Feinmark SJ, Cannon PJ. Endothelial cell leukotriene C4 synthesis results from intercellular transfer of leukotriene A4 synthesized by polymorphonuclear leukocytes. J Biol Chem. 1986;261(35):16466-72. (Pubitemid 17000830)
70. Tamosiuniene R, Nicolls MR. Regulatory T cells and pulmonary hypertension. Trends Cardiovasc Med. 2011;21(6):166-71.
71. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res. 2011;109(8):867-79.
72. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12):849-59.
73. Rubin LJ. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008;34(1):191-7 viii.
74. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527-38. (Pubitemid 351508372)
75. Smedegard G, Hedqvist P, Dahlen SE, Revenas B, Hammarstrom S, Samuelsson B. Leukotriene C4 affects pulmonary and cardiovascular dynamics in monkey. Nature. 1982;295(5847):327-9. (Pubitemid 12159265)
76. Weiss JW, Drazen JM, Coles N, McFadden ER Jr, Weller PF, Corey EJ, Lewis RA, Austen KF. Bronchoconstrictor effects of leukotriene C in humans. Science. 1982;216(4542):196-8. (Pubitemid 12089845)
77. Hanna CJ, Bach MK, Pare PD, Schellenberg RR. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature. 1981;290(5804):343-4. (Pubitemid 11107251)
78. Stenmark KR, James SL, Voelkel NF, Toews WH, Reeves JT, Murphy RC. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. New Engl J Med. 1983;309(2):77-80. (Pubitemid 13063590)
79. Dobyns EL, Wescott JY, Kennaugh JM, Ross MN, Stenmark KR. Eicosanoids decrease with successful extracorporeal membrane oxygenation therapy in neonatal pulmonary hypertension. Am J Respir Crit Care Med. 1994;149(4 Pt 1):873-80. (Pubitemid 24108474)
80. Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2013. doi:10.1517/14740338.2014.859674.